Alcon presents new clinical research on dry eye drug TRYPTYR at Academy 2026
ALC•Alcon outlined new research on TRYPTYR (acoltremon) 0.003% ahead of Academy 2026 in Anaheim, with findings scheduled for Sept. 30–Oct. 3.
1. Research presentations
The research will focus on patient-reported quality of life, daily functioning, symptoms and treatment satisfaction. Additional posters will compare outcomes across Alcon’s prescription and over-the-counter dry eye portfolio, including tear film-related measures. The update follows the U.S. launch of TRYPTYR.
